Please provide your email address to receive an email when new articles are posted on . After one dose of Tremfya patients experienced significant improvements in body and scalp psoriasis. The VISIBLE ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tremfya showed greater persistence in bio-naïve and ...
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients. While one sBLA seeks approval ...
LAS VEGAS, Oct. 19, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial ...
Johnson & Johnson is chasing giants in immunology with a plaque psoriasis nod from the FDA––and fast-growing sales––to show for it so far. Not content with that, though, Tremfya is pushing toward ...
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has received approval from the US Food and Drug Administration (FDA) for paediatric patients with plaque psoriasis and active psoriatic arthritis. This ...
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate ...
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of ...
THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...
Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...
"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback